<DOC>
	<DOCNO>NCT00583297</DOCNO>
	<brief_summary>The ABCD clinical study ( ClinicalTrials.gov Identifier NCT00187291 ) design determine T-Wave Alternans ( TWA ) test equivalent Electrophysiology Study ( EPS ) predict life-threatening heart rhythm patient ischemic heart disease , leave ventricular dysfunction , non-sustained tachycardia . The purpose ABCD Genetic sub-study identify genetic marker predict TWA status arrhythmia risk population .</brief_summary>
	<brief_title>Genetic Substudy Alternans Before Cardioverter Defibrillator ( ABCD ) Trial</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Tachycardia</mesh_term>
	<mesh_term>Tachycardia , Ventricular</mesh_term>
	<criteria>Subjects previously enrol ABCD trial sponsor St. Jude Medical ( ClinicalTrials.gov Identifier NCT00187291 ) patient ischemic heart disease leave ventricular ejection fraction ( LVEF ) &lt; 40 % nonsustained ventricular tachycardia Individuals previously enrol ABCD trial eligible genetic substudy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Arrhythmia</keyword>
	<keyword>Heart Failure</keyword>
	<keyword>T wave Alternans ( TWA )</keyword>
	<keyword>Implanted Cardioverter Defibrillator ( ICD )</keyword>
	<keyword>Biological Markers</keyword>
	<keyword>Molecular Genetics</keyword>
</DOC>